Whalesbook
A new report reveals a widening gap between the escalating global health threat of antimicrobial resistance (AMR) and the pharmaceutical industry's innovation efforts. The findings indicate the current model for developing new antimicrobials is insufficient to meet the growing challenge, requiring new approaches to investment and collaboration.
The Widening Gap in Drug Development
Antimicrobial resistance (AMR) is rapidly outpacing the pharmaceutical industry's ability to respond. The latest AMR Benchmark report highlights seven promising late-stage projects from companies like GSK and Shionogi targeting deadly drug-resistant pathogens. However, these are insufficient to meet the growing threat. Over one million people now die annually from drug-resistant infections, a number projected to nearly double to two million by 2050. The total annual deaths attributed to AMR could soar from over four million to more than eight million within the same period. This rising mortality, coupled with a shrinking pipeline for new medicines, signals a significant challenge in tackling this global health crisis. Shionogi, for example, shows progress with a P/E ratio of 14.36, while GSK has a P/E ratio of 15.1, indicating their market valuations.
Shrinking Pipelines and Company Performance
The development of new medicines for infectious diseases has declined notably, driven by chronic underinvestment and reduced private sector interest. The performance of both large research firms and generic manufacturers has weakened since the 2021 AMR Benchmark report. GSK and Aurobindo Pharma stand out for registering child-friendly formulations, and Shionogi shows strong progress. However, the overall industry R&D output is contracting. Aurobindo Pharma, with a P/E ratio of 19.4, is recognized for accessible formulations but faces modest operating profit growth (3.23% CAGR over five years). Smaller biotech firms are showing innovation, though their scale limits broad impact.
Global Access Gaps Remain
Significant disparities persist in accessing antimicrobial treatments. While companies like GSK, Hikma, Sandoz, Teva, and Aurobindo Pharma have registered more child-friendly formulations, countries in sub-Saharan Africa remain largely overlooked. The limited pipeline is worsened by long approval times for pediatric formulations. In low- and middle-income countries (LMICs), access to essential pediatric antibiotics is often inadequate, leading to suboptimal treatments that can fuel further resistance and disproportionately affect vulnerable populations.
Investment Challenges Hamper Development
Experts note that chronic underinvestment and weak R&D pipelines are hampering antimicrobial development. The structural economic challenge for antibiotics—short usage durations compared to chronic disease treatments—diminishes commercial appeal and return on investment. This leads to underfunding, where R&D costs and long timelines outweigh perceived market size. Investors now see AMR as a systemic risk, with potential global economic costs reaching $100 trillion by 2050, spurring calls for stronger government action and new payment models. Venture funding for infectious diseases saw a rebound in Q3 2025 ($369 million across 12 rounds), but this follows a quiet period. The high failure rate in antibiotic development is evident, with companies like Pulmocide facing setbacks, such as the termination of its Phase II trial for opelconazole in January 2026. Analyst sentiment for major players like GSK is mixed, with a consensus 'Reduce' rating and a forecasted downside of -20.51%. Aurobindo Pharma holds a 'Hold' rating, noting modest growth and premium valuation. These factors, including looming patent expirations, create significant challenges for the sector.
Collaboration and Solutions Needed
Experts emphasize that practical approaches exist to accelerate progress. Jayasree K. Iyer, Chief Executive of the Access to Medicine Foundation, highlighted the potential for practical solutions. John-Arne Røttingen, CEO of Wellcome, stressed the need for diverse partnerships involving private companies, researchers, public and philanthropic funders, and innovative payment models. The AMR Benchmark report evaluated 25 companies, identifying real-world actions to curb drug resistance. For instance, Shionogi achieved ISO 14001 certification for its antimicrobial manufacturing processes, demonstrating a commitment to environmental standards.
Looking Ahead: Funding and Analyst Views
The path forward depends on new investment mechanisms and collaboration. Experts advocate for public-private partnerships and payment models that reduce R&D risk and ensure equitable access. The market is increasingly focused on companies showing both innovation and a commitment to responsible use and global access. The broader biopharmaceutical industry has seen a funding rebound, though R&D deal volumes have declined, indicating a more selective investment approach. Emerging biopharma companies often partner with larger firms, suggesting a hybrid model for innovation. Analyst consensus for Aurobindo Pharma is a 'Buy' with a price target of 1,345.19 INR, indicating potential upside. However, systemic challenges in antimicrobial development persist.